Connect public, paid and private patent data with Google Patents Public Datasets

Inhibitors of the mutant form of kit

Download PDF

Info

Publication number
US20120157441A1
US20120157441A1 US13357972 US201213357972A US2012157441A1 US 20120157441 A1 US20120157441 A1 US 20120157441A1 US 13357972 US13357972 US 13357972 US 201213357972 A US201213357972 A US 201213357972A US 2012157441 A1 US2012157441 A1 US 2012157441A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
kit
mutant
del
form
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13357972
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Elisabeth Buchdunger
Doriano Fabbro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance

Abstract

The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.

Description

  • [0001]
    The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.
  • [0002]
    The c-kit gene encodes a receptor protein tyrosine kinase, which is herein referred to as KIT, but which is also known as mast/stem cell growth factor receptor. The amino acid sequence of KIT and the nucleotide sequence of the c-kit gene are known. See Swiss Prot.: P10721. Upon binding its ligand, stem cell factor, KIT forms a dimer that is autophosphorylated and activates signaling cascades that lead to cell growth. Mutations that lead to an activated form of KIT, especially forms that are activated independently of its ligand, are known and are believed to play a role in certain proliferative diseases, such as mast cell diseases, like mastocytosis, particularly systemic mastocytosis, acute myelogenous leukemia, gastrointestinal stromal tumors, sinonasal NK/T-cell lymphoma, seminomas and dysgerminomas.
  • [0003]
    Imatinib, which is marketed as its mesylate salt under the brandname GLIVEC or GLEEVEC, is known to inhibit wild type KIT and certain KIT mutations e.g. those in exons commonly found in gastrointestinal stromal tumors (GIST). However, it is also inactive or significantly less active against certain other mutant forms of KIT, for example the D816V mutation commonly found in systemic mastocytosis. The present invention is based upon research that correlates the treatment of a disease characterized by a mutant form of KIT with an appropriate alternative pharmaceutical therapy based on the alternative's ability to inhibit the mutant KIT.
  • [0004]
    Thus, the present invention relates to a method of treating a KIT dependent disease in a patient, which comprises
      • (a) identifying the mutant form of KIT associated with the KIT dependent disease; and
      • (b) administering to the patient an effective mutant KIT-inhibiting amount of an inhibitor selected from the group consisting of midostaurin, vatalanib and compound A.
  • [0007]
    KIT dependent diseases are generally proliferative diseases that are characterized by excessive KIT kinase activity due to an activating mutation in KIT. Such activating mutations are known in the art and are identified by techniques known in the art.
  • [0008]
    KIT dependent diseases include diseases characterized by the following known KIT mutations: D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 557-561, N822K, V654A, N822H, Del 550-558+V654A, Del 557-561+V654A, Ins503AY, V560G, 558NP, Del 557-558, Del W559-560, F522C, Del 579, R634W, K642E, T801I, C809G, D820Y, N822K, N822H, Y823D, Y823C and T670I.
  • [0009]
    In an important embodiment of the present invention, the KIT dependent disease is resistant to treatment with imatinib. A KIT dependent disease that is resistant to imatinib is generally a KIT dependent disease as described above wherein imatinib, administered at a dose of 400-1000 mg/day, does not provide sufficient inhibition of the mutant KIT to effect a significant therapeutic benefit. Generally, mutant KIT that is resistant to imatinib has an in vitro IC50 of the mutant KIT greater than about 3 micromolar. Imatinib resistant KIT mutations include D816F, D816H, D816N, D816Y, D816V, T670I and mutant forms that include V654A.
  • [0010]
    The selection of a compound that inhibits the mutant form of KIT is based on testing the compound or a number of compounds for their ability to inhibit the mutant KIT. Such testing is carried out by standard inhibition assays that are known in the art or within the skill of the artisan.
  • [0011]
    The KIT inhibitors utilized in accordance with the present method include midostaurin, vatalanib and compound A. Midostaurin (U.S. Pat. No. 5,093,330) and vatalanib (WO 98/35958) are known in the art. Compound A is a compound of the formula
  • [0000]
  • [0012]
    And may be produced according to WO 04/005281.
  • [0013]
    Appropriate dosages of midostaurin, vatanalib and compound A are determined by routine methods.
  • [0014]
    An appropriate dose of midostaurin is administered, e.g., once, twice or three times a day, for a total dose of 25-300 preferably 50-300 more preferably 50-100 most preferably 100-300 mg daily, e.g., two or three times a day, for a total dose of 150-250 mg, preferably 225 mg daily.
  • [0015]
    An appropriate daily dose of vatanalib is an amount in the range from 300-4000 mg, e.g., in the range from 300-2000 mg/day or 300-1500 mg/day, in particular, 300, 500, 750, 1000, 1250, 1500 or 2000 mg/day, particularly 1250 mg/day.
  • [0016]
    The daily dose of compound A for a 70 kg/person is from approximately 0.05-5 g, preferably from approximately 0.25-1.5 g.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0017]
    FIG. 1 illustrates mutant insertion points in the Bac-to-Bac donor vector pFB-GST-01.
  • EXAMPLES
  • [0018]
    The human KIT gene encoding aa 544-976 was cloned into the baculovirus donor plasmid pFB-GST-01. This coding sequence was excised using restriction endonucleases Barn H1 and EcoR1 and ligated to a Bac-to-Bac donor vector pFB-GEX-P1 with compatible ends. Subsequently the desired mutations were brought into the KIT gene by methods know to a person skilled in the art. Due to a frame shift within the original plasmid that was used to generate the mutant coding sequences, the mutated plasmid inserts were excised and inserted into the Bac-to-Bac donor vector pFB-GST-01 using the restriction enzymes BamH1-EcoR1 for each mutant shown in FIG. 1. Automated sequencing confirmed the correct sequence to be present for each mutant plasmid.
  • [0019]
    Bacmid DNA was generated from 10 colonies each of DH10Bac cells transformed with pFB-G01-KIT-mutant plasmid clones as described in materials and methods and these transfected into Sf9 cells. The transfected cells were pelleted and the resultant recombinant baculovirus present in the supernatant medium amplified. Western blotting was applied to the lysed cell pellets to confirm the expression of the GST-c-KIT fusion protein by the viral clones using anti-KIT and anti-GST antibodies for immonudetection.
  • [0000]
    Vatalanib Compound A
    Kit Mutation IC50 (μM) (avg) IC50 (μM) (avg)
    D816F >10 >10
    D816H >10 >10
    D816N >10 <10
    D816Y >10 >10
    D816V >10 >10
    K642E <1 <10
    Y823D <1 <1
    Del 550-558 <1 <2
    Del 557-561 <1 <2
    N822K <2 <10
    V654A >10 >10
    N822H <2 <10
    Del 550-558 + V654A <10 <10
    Del 557-561 + V654A >10 >10
    Midostaurin
    average N° of
    IC50 μM SEM values
    HIS preparation
    HT-KIT-TA23 wt 1.7 0.15 2
    HT-KIT TA23 − D820G 0.084 0.05 2
    HT-KIT TA23 − T670I 0.89 0.21 2
    GST preparation
    GST-KIT wt 1.8 0.26 10
    GST-KIT Del 557-561 0.32 0.042 3
    GST-KIT Del 550-558 0.53 0.057 3
    GST-KIT Del 550-558 + V654A 0.27 0.079 5
    GST-KIT Del 557-561 + V654A 0.34 0.11 5
    GST-KIT V654A 0.46 0.16 5
    GST-KIT K642E 0.64 0.036 4
    GST-KIT R634W 0.33 0.13 2
    GST-KIT T670I + Del 550-558 0.11 0.05 2
    GST-KIT D816F 0.41 0.055 5
    GST-KIT D816H 0.35 0.078 5
    GST-KIT D816N 0.74 0.25 5
    GST-KIT D816Y 0.29 0.11 9
    GST-KIT D816V 0.25 0.039 3
    GST-KIT D816H + R634W 0.08 0.04 2
    GST-KIT N822H 0.37 0.12 5
    GST-KIT N822K 0.15 0.058 5
    GST-KIT Y823D 0.13 0.0075 3

    Assay conditions: 1 μM ATP, 5 μg/ml Poly-EY, 10 min incubation at ambient temperature
  • [0020]
    Virus containing media was collected from the transfected cell culture and used for infection to increase its titer. Virus containing media obtained after two rounds of infection was used for large-scale protein expression. For large-scale protein expression 100 cm2 round tissue culture plates were seeded with 5×107 cells/plate and infected with 1 mL of virus-containing media (approximately 5 MOIs). After 3 days, the cells were scraped off the plate and centrifuged at 500 rpm for 5 minutes. Cell pellets from 10-20, 100 cm2 plates, were re-suspended in 50 mL of ice-cold lysis buffer (25 mM Tris-HCl, pH 7.5, 2 mM EDTA, 1% NP-40, 1 mM DTT, 1 mM PMSF). The cells were stirred on ice for 15 minutes and then centrifuged at 5000 rpm for 20 minutes.
  • [0021]
    The centrifuged cell lysate was loaded onto a 2 mL glutathione-sepharose column (Pharmacia) and washed 3× with 10 mL of 25 mM Tris-HCl, pH 7.5, 2 mM EDTA, 1 mM DTT, 200 mM NaCl. The GST-tagged proteins were then eluted by 10 applications (1 mL each) of 25 mM Tris-HCl, pH 7.5, 10 mM reduced-glutathione, 100 mM NaCl, 1 mM DTT, 10% glycerol and stored at −70° C.
  • [0022]
    The protein kinase activities of the various Kit mutants 200-500 ng were assayed in the presence or absence of inhibitors, 20 mM Tris-HCl, pH 7.6, 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, 10 μM Na3VO4, 3 μg/mL poly(Glu,Tyr) 4:1, 1% DMSO, 1.5 μM ATP (γ-[33P]-ATP 0.1 μCi). The assay (30 μL) was carried out in 96-well plates at ambient temperature for 30 minutes and the reaction terminated by the addition of 20 μL of 125 mM EDTA. Subsequently, 30 μl of the reaction mixture were transferred onto Immobilon-PVDF membrane (Millipore, Bedford, Mass., USA) previously soaked for 5 minutes with methanol, rinsed with water, then soaked for 5 minutes with 0.5% H3PO4 and mounted on vacuum manifold with disconnected vacuum source. After spotting all samples, vacuum was connected and each well rinsed with 200 μL 0.5% H3PO4. Membranes were removed and washed 4× on a shaker with 1.0% H3PO4, once with ethanol. Membranes were counted after drying at ambient temperature, mounting in Packard TopCount 96-well frame, and addition of 10 μL/well of Microscint (Packard). IC50 values were calculated by linear regression analysis of the percentage inhibition of each compound in duplicate, at 4 concentrations (usually 0.01, 0.1, 1 and 10 μM). One unit of protein kinase activity is defined as 1 nmole of 33P transferred from [γ33P]ATP to the substrate protein/minute/mg of protein at RT.

Claims (24)

1. A method of treating a KIT dependent disease in a patient, which comprises: (a) identifying a mutant form of KIT associated with the KIT dependent disease; and (b) administering to said patient an effective mutant KIT inhibiting amount of an inhibitor selected from the group consisting of midostaurin and vatalanib.
2. A method of claim 1, wherein the mutant form of KIT is selected from D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 557-561, N822K, V654A, N822H, Del 550-558+V654A, Del 557-561+V654A, Ins503AY, V560G, 558NP, Del 557 558, Del W559-560, F522C, Del 579, R634W, K642E, T8011, C809G, D820Y, N822K, N822H, Y823D, Y823C and T6701.
3. A method of claim 2, wherein the mutant form of KIT is selected from D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 557-561, N822K, V654A, N822H, Del 550-558+V654A, Del 557-561+V654A.
4. A method of claim 1, wherein the KIT dependent disease is resistant to treatment with imatinib.
5. A method of claim 3, wherein the mutant form of KIT is D816F and the inhibitor is selected from the group consisting of midostaurin.
6. A method of claim 3, wherein the mutant form of KIT is D816H and the inhibitor is selected from the group consisting of midostaurin.
7. A method of claim 3, wherein the mutant form of KIT is D816N and the inhibitor is selected from the group consisting of midostaurin.
8. A method of claim 3, wherein the mutant form of KIT is D816Y and the inhibitor is selected from the group consisting of midostaurin.
9. A method of claim 3, wherein the mutant form of KIT is D816V and the inhibitor is selected from the group consisting of midostaurin.
10. A method of claim 3, wherein the mutant form of KIT is K642E and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
11. A method of claim 3, wherein the mutant form of KIT is Y823D and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
12. A method of claim 3, wherein the mutant form of KIT is Del 550-558 and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
13. A method of claim 3, wherein the mutant form of KIT is Del 557-561 and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
14. A method of claim 3, wherein the mutant form of KIT is N822K and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
15. A method of claim 3, wherein the mutant form of KIT is V654A and the inhibitor is selected from the group consisting of midostaurin.
16. A method of claim 3, wherein the mutant form of KIT is N822H and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
17. A method of claim 3, wherein the mutant form of KIT is Del 550-558 V654A and the inhibitor is selected from the group consisting of midostaurin and vatalanib.
18. A method of claim 3, wherein the mutant form of KIT is Del 557-561+V654A and the inhibitor is selected from the group consisting of midostaurin.
19. A method of claim 2, wherein the mutant form of KIT is selected from the group consisting of D816H, D816F, D816N and D816Y and the inhibitor is midostaurin.
20. A method of claim 2, wherein the mutant form of KIT is selected from the group consisting of D816V, K642E, Y823D, De1550-558, Del 557-561, N822K, V654A, N822H, Del 550-558+V654A, and Del 557-561+V654A and the inhibitor is midostaurin.
21. A method of claim 2, wherein the mutant form of KIT is selected from the group consisting of K642E, Y823D, Del 550-558, Del 557-561, N822K and N822H and the inhibitor is vatalanib.
22. A method according to claim 1, wherein the KIT dependent disease is selected from mast cell diseases, acute myelogenous leukemia, gastrointestinal stromal tumors, seminomas and dysgerminomas.
23. A method of claim 4, wherein the inhibitor is midostaurin.
24. A method of claim 4, wherein the inhibitor is vatalanib.
US13357972 2003-11-18 2012-01-25 Inhibitors of the mutant form of kit Abandoned US20120157441A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US52071403 true 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit
US57958607 true 2007-01-17 2007-01-17
US12700106 US8124611B2 (en) 2003-11-18 2010-02-04 Inhibitors of the mutant form of kit
US13357972 US20120157441A1 (en) 2003-11-18 2012-01-25 Inhibitors of the mutant form of kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13357972 US20120157441A1 (en) 2003-11-18 2012-01-25 Inhibitors of the mutant form of kit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12700106 Division US8124611B2 (en) 2003-11-18 2010-02-04 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
US20120157441A1 true true US20120157441A1 (en) 2012-06-21

Family

ID=34619508

Family Applications (3)

Application Number Title Priority Date Filing Date
US10579586 Active 2026-11-25 US8017621B2 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit
US12700106 Active 2025-01-21 US8124611B2 (en) 2003-11-18 2010-02-04 Inhibitors of the mutant form of kit
US13357972 Abandoned US20120157441A1 (en) 2003-11-18 2012-01-25 Inhibitors of the mutant form of kit

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10579586 Active 2026-11-25 US8017621B2 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit
US12700106 Active 2025-01-21 US8124611B2 (en) 2003-11-18 2010-02-04 Inhibitors of the mutant form of kit

Country Status (11)

Country Link
US (3) US8017621B2 (en)
JP (3) JP4762150B2 (en)
KR (1) KR101153647B1 (en)
CN (3) CN1882344A (en)
CA (1) CA2546189C (en)
DE (1) DE602004020654D1 (en)
DK (1) DK1686997T3 (en)
EP (2) EP1686997B1 (en)
ES (1) ES2324917T3 (en)
RU (2) RU2405553C1 (en)
WO (1) WO2005049032A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112794A3 (en) 2003-06-18 2005-06-16 Novartis Ag New pharmaceutical uses of staurosporine derivatives
KR101153647B1 (en) 2003-11-18 2012-06-18 노파르티스 아게 Inhibitors of the mutant form of kit
WO2006024494A1 (en) * 2004-08-31 2006-03-09 Novartis Ag Use of midostaurin for treating gastrointestinal stromal tumors
RU2445960C2 (en) 2005-05-02 2012-03-27 Новартис Аг Use of pyrimidylaminobenzamide derivatives for treating systemic mastocytosis
ES2593319T3 (en) 2005-05-02 2016-12-07 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
JP5322639B2 (en) * 2005-07-20 2013-10-23 ペーター・ヴァレントPeter VALENT Systemic mastocytosis treatment for composition
EP2535337B1 (en) * 2005-07-20 2017-08-23 Novartis AG Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form
ES2549327T3 (en) * 2005-12-06 2015-10-27 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Complex drug
US20100298338A1 (en) * 2008-01-23 2010-11-25 Yanfeng Wang Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit
WO2015082887A3 (en) * 2013-12-02 2015-07-30 Bergenbio As Use of kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096864A1 (en) * 2003-09-19 2008-04-24 Sasa Dimitrijevic Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE10299016I2 (en) 1992-04-03 2006-08-24 Novartis Ag Pyrimidine derivatives and processes for their preparation
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
JPH08503971A (en) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト Pyrimidinamine derivatives and methods for their preparation
EP0723533A1 (en) 1993-10-12 1996-07-31 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
DK0970070T3 (en) 1997-02-13 2005-02-14 Novartis Ag Phthalazines of angiogenesis-inhibiting activity
GB9711377D0 (en) 1997-06-03 1997-07-30 Polybiomed Ltd Treating metal sufaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
ES2209194T3 (en) 1997-07-18 2004-06-16 Novartis Ag Crystal modification derivative of n-phenyl-2-pyrimidinamine, processes for their manufacture and use.
WO1999025372A1 (en) 1997-11-13 1999-05-27 Histatek, Llc Small peptides and methods for treatment of asthma and inflammation
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
US20040157855A1 (en) 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
US20050054617A1 (en) 2001-06-29 2005-03-10 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
CA2453108A1 (en) 2001-07-19 2003-01-30 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CN1625602A (en) * 2002-03-13 2005-06-08 霍夫曼-拉罗奇有限公司 Method for selecting drug sensitivity decision factor and method for predetermining drug sensitivity using the selected factor
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
WO2004112794A3 (en) 2003-06-18 2005-06-16 Novartis Ag New pharmaceutical uses of staurosporine derivatives
KR101153647B1 (en) 2003-11-18 2012-06-18 노파르티스 아게 Inhibitors of the mutant form of kit
RU2445960C2 (en) 2005-05-02 2012-03-27 Новартис Аг Use of pyrimidylaminobenzamide derivatives for treating systemic mastocytosis
CN200998572Y (en) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 Golf club head cover capable of carrying repair piece
JP5448036B2 (en) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 Method for producing a carboxylic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096864A1 (en) * 2003-09-19 2008-04-24 Sasa Dimitrijevic Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HHMI (Howard Hughes Medical Institute) Research News, "Drug-Resistant Cancer Outwitted by Chemical Flank Attack", May 20, 2003, 3 pages. *
Tian et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999 Jun;154(6):1643-7. *
U.S. Provisional application No. 60/504,245, filed 09/19/2003. *

Also Published As

Publication number Publication date Type
EP1686997B1 (en) 2009-04-15 grant
EP1686997A1 (en) 2006-08-09 application
CN102274230B (en) 2015-07-01 grant
KR20060101761A (en) 2006-09-26 application
JP2013241438A (en) 2013-12-05 application
US20070213317A1 (en) 2007-09-13 application
CA2546189A1 (en) 2005-06-02 application
CN101693031A (en) 2010-04-14 application
DK1686997T3 (en) 2009-07-27 grant
DE602004020654D1 (en) 2009-05-28 grant
JP4762150B2 (en) 2011-08-31 grant
CA2546189C (en) 2013-04-23 grant
US8017621B2 (en) 2011-09-13 grant
RU2009110449A (en) 2010-09-27 application
WO2005049032A1 (en) 2005-06-02 application
JP2011121973A (en) 2011-06-23 application
JP2007511567A (en) 2007-05-10 application
US20100179179A1 (en) 2010-07-15 application
EP1917965A1 (en) 2008-05-07 application
RU2006121447A (en) 2008-01-10 application
US8124611B2 (en) 2012-02-28 grant
CN102274230A (en) 2011-12-14 application
RU2362562C2 (en) 2009-07-27 grant
RU2405553C1 (en) 2010-12-10 grant
ES2324917T3 (en) 2009-08-19 grant
KR101153647B1 (en) 2012-06-18 grant
CN1882344A (en) 2006-12-20 application

Similar Documents

Publication Publication Date Title
Tsao et al. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B
Boyce et al. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress
Sattler et al. Critical role for Gab2 in transformation by BCR/ABL
Tsai et al. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation
Andreassen et al. Neither p21WAF1 nor 14-3-3σ prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells
US6908920B2 (en) Pyrimidine derivatives
Jin et al. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1
US20020132754A1 (en) Selective PDE 2 inhibitors as pharmaceuticals for improving perception
Mortlock et al. Progress in the development of selective inhibitors of aurora kinases
Kuwahara et al. Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes
Afar et al. Regulation of Btk by Src family tyrosine kinases.
Wagman et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes
Li et al. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer
Goldstein et al. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development
Weisberg et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
Vermeulen et al. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
US20090253634A1 (en) Methods and Compositions for the Treatment of Gastrointestinal Disorders
US6420338B1 (en) Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
US20030125343A1 (en) Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
Nardi et al. Mechanisms and implications of imatinib resistance mutations in BCR-ABL
Blake et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling
Li Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
Romero et al. Bis (heteroaryl) piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogs and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl) carbonyl]-4-[3-[(1-methylethyl) amino] pyridinyl] piperazinemonomethanesulfonate (U-90152S), a second-generation clinical candidate
US20060058339A1 (en) Compounds modulating c-kit activity and uses therefor
Tyler et al. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells